1
Een shown to be similar to adalimumab with respect to binding to a panel of Fc receptors, including FccRIa, FccRIIa, FccRIIIa (158V) (with and without TNFa), and FccRIIIa (158F). Importantly, effector function activation (ADCC and CDC) was also demonstrated to be similar between ABP 501 and adalimumab using highly sensitive methods. The ADCC and CDC methods have been demonstrated to be sensitive t
1
Function testing. Teresa L. Born is the corresponding author and is responsible for the overall design and execution of the studies. Yuh-feng Chen is the subject expert for potency assessment and he contributed to the authoring and reviewing of this manuscript. Amanda Rohrbach, Christina Pastula, and Gwen Maher are the subject experts for binding assays and they contributed to the authoring and re
1
Manuscript.Compliance with Ethical Standards Amgen Inc. conducted and funded all analyses. Amgen Inc. also provided funding for medical writing and editorial support to MedVal Scientific Information Services, LLC, Skillman, NJ, USA. This article does not contain any studies with human participants or animals performed by any of the authors. This paper was prepared according to the ICMJE Uniform Re